Signal from the log
Celaid Therapeutics
400 M JPY · Series B · Japan · Biotech
Celaid Therapeutics, à Tokyo, multiplie en laboratoire des cellules souches du sang pour des greffes destinées à des enfants atteints de maladies graves non cancéreuses. Shionogi et Teikoku Ventures entrent au capital avant un premier essai chez l'humain aux États-Unis.
Verified
Announced on , logged by the watch of 5 October 2026.
- Operation
- Funding round
- Announced amount
- 400 M JPY
- Stage
- Series B
- Country
- Japan
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
With Shionogi , Teikoku Ventures
Provenance
Source prnewswire,pulse2
Logged on 5 October 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.